Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,510.00
Bid: 12,524.00
Ask: 12,526.00
Change: 118.00 (0.95%)
Spread: 2.00 (0.016%)
Open: 12,468.00
High: 12,556.00
Low: 12,434.00
Prev. Close: 12,392.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Opening snapshot: buying retailers, eyes on the Fed

Wed, 16th Sep 2020 08:44

Welcome to the home for real-time coverage of European equity markets brought to you by Reuters
stocks reporters. You can share your thoughts with Joice Alves (joice.alves@thomsonreuters.com)
and Julien Ponthus (julien.ponthus@thomsonreuters.com) in London and Danilo Masoni
(danilo.masoni@thomsonreuters.com) and Stefano Rebaudo (stefano.rebaudo@thomsonreuters.com) in
Milan.

OPENING SNAPSHOT: BUYING RETAILERS, EYES ON THE FED (0743 GMT)

European stocks are slightly higher, supported by the retail sector after stronger than
expected results from Zara owner Inditex.

Investors are reluctant to take big positions ahead of today's Federal Reserve policy
meeting. Their focus is on the central bank's economic view with some expectations it might take
further steps on the accommodative side.

Travel and leisure stocks are still under pressure after Lufthansa said it could
cut its fleet by 130 planes, 30 planes more than recently panned.

Europe's STOXX 600 index is up 0.2% led by Retailers, up 1.4%, while Travel and
Leisure stocks are the worst performers, down 0.4%

Inditex is up 5.5% after the company returned to quarterly profit though reported
sales down 31% on the year-ago period. Sweden’s Handelsbanken is up 3.3% as the
company will reduce its workforce and number of branches.

A whooping 30% rise for The Hut Group in its first day of trading on the London
Stock Exchange to seal the first major British initial public offering since the start of the
COVID-19 crisis.

(Stefano Rebaudo)

*****

ON THE RADAR: ASTRAZENECA, THE HUT GROUP, HANDELSBANKEN (0644 GMT)

European stocks are set to open slightly lower as investors wait for Federal Reserve policy
statement and economic view later today.

Vaccine developments are still on the frontline after the U.S. Food and Drug Administration
confirmed AstraZeneca's U.S. COVID-19 vaccine trial is on hold, as it conducts its
investigation after an illness in a participant in Britain.

Meanwhile in India, the local drugs regulator has given approval to Serum Institute of India
to resume clinical trials of the potential vaccine developed by AstraZeneca and Oxford
University, according to a Times of India report.

In London, e-commerce firm The Hut Group is preparing for its first day of trading
after batting away corporate governance concerns to seal the first major British initial public
offering since the start of the COVID-19 crisis.

Elsewhere, Handelsbanken will reduce its number of branches to around 200 from 380
by the end of 2021 and reduce its workforce, affecting around 1,000 employees in Sweden over the
next two years, as part of a review of the group's business operations.

Eyes also on Lufthansa which could cut its fleet by 130 planes in response to the
coronavirus crisis, 30 planes more than recently panned.

In results, fashion retailer Inditex, owner of Zara, returned to quarterly profit
in the three months from May to July but reported sales down 31% on the year-ago period.

There could be a positive readacross for Deutsche Post and Royal Mail
from stronger than expected results at U.S. delivery firm FedEx.

Finally Atlantia is ready to approve the listing of its motorway assets as early as
next week, challenging the solution favoured by the Rome government to solve a long-running
dispute with the infrastructure group.

(Stefano Rebaudo)

*****

MORNING CALL: WAITING FOR THE FED (0528 GMT)

European stock futures are hovering around yesterday levels with no clear direction as
investors await a Federal Reserve policy statement later today.

Yesterday’s upbeat U.S. and China macro data increased risk sentiment, but concerns about
the economy remain on fears of a second wave of virus-induced restrictions as well as a
political impasse over a new relief package in the U.S.

The Fed policy meeting which ends today is the first one since chairman Jerome Powell
announced a new stance on inflation and some analysts hope the U.S. central bank might take a
step forward on the accommodative side.

(Stefano Rebaudo)

*****

More News
12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

Read more
10 Jun 2024 09:10

LONDON BROKER RATINGS: JPMorgan cuts Aviva but lifts M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday:

Read more
10 Jun 2024 08:30

TOP NEWS: Astra's Tagrisso gets US priority review for lung cancer

(Alliance News) - AstraZeneca PLC on Monday celebrated a breakthrough therapy designation for its cancer drug Tagrisso, aimed at treating a form of non-small cell lung cancer.

Read more
10 Jun 2024 07:37

LONDON BRIEFING: FTSE called down amid political uncertainty in EU

(Alliance News) - Stocks in London are called to open lower on Monday, setting off the week on the backfoot, with eyes on the US Federal Reserve's latest interest rate decision.

Read more
10 Jun 2024 06:25

London pre-open: Stocks set for lower start after EU elections

(Sharecast News) - Stocks in London look primed for a lower start as investors digest the gains made by far right parties in Austria, Germany, but above all France, at the European Union elections that were held at the weekend.

Read more
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more
3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
3 Jun 2024 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.